The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
PI3K/AKT/mTOR Pathway in Angiogenesis
Open accessAbstract
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is activated in the majority of human cancers. This pathway is known to play a key role in numerous cellular functions including proliferation, adhesion, migration, invasion, metabolism, and survival, but in the current review we focus on its role in angiogenesis. PI3K activation may occur via RAS mutation, loss of phosphatase and tensin homolog (PTEN), or by increased expression of growth factor receptors such as epidermal growth factor receptor. There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to HIF-1α stabilization and is a major stimulus for increased vascular endothelial growth factor (VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) dependent and independent mechanisms. The PI3K/AKT pathway also modulates the expression of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on tumor vasculature can be difficult to predict. The vasculature of tumors is aberrant, leading to sluggish bloodflow and elevated interstitial blood pressure, which can be perpetuated by the high levels of VEGF. Hence, decreasing VEGF expression can paradoxically lead to vascular normalization and improved bloodflow in some tumors. In addition to its importance in cancer, the PI3K pathway also plays an essential role in the formation of normal blood vessels during development. Embryos with kinase-dead p110α catalytic subunit of PI3K develop vascular defects. Stimulation of endothelial cells by VEGF leads to activation of the PI3K pathway within these cells, which is important for cell migration. Sustained endothelial activation of AKT1 has been shown to induce the formation of structurally abnormal blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway plays an important role in regulating angiogenesis both in normal tissues and in cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kasuno, K., Takabuchi, S., Fukuda, K., Kizaka-Kondoh, S., Yodoi, J., Adachi, T., Semenza, G. L., & Hirota, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308197200 · Cited by 226
RetractedTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 2×
“HIF-1α is upregulated across a broad range of cancers, and HIF regulates key features of tumor biology such as angiogenesis, invasion, and glucose metabolism (Ratcliffe et al., 2000; Semenza, 2003).”
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591 · cited 1×
“This regulation may occur via phosphorylation of eNOS at the serine 1177 residue by AKT (Dimmeler et al., 1999; Fulton et al., 1999).”
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
(1989) · PubMed · Cited by 3,343
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Role of angiogenesis in tumor growth and metastasis
Folkman, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37263 · Cited by 2,404
Role of angiogenesis in tumor growth and metastasis
FOLKMAN, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,400
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81812-7 · Cited by 1,989 · cited 1×
“While ANGl is required for endothelial development, ANG2 is an antagonist of the ANGl/TIE2 system and can disrupt blood vessel formation (Davis et al., 1996; Maisonpierre et al., 1997).”
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
(2000) · PubMed · Cited by 1,445
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355
Signalling through the lipid products of phosphoinositide-3-OH kinase
Toker, A., & Cantley, L. C. (1997) · Nature · doi:10.1038/42648 · Cited by 1,304
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T. S., Bochenek, M. L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Lüthi, U., et al. (2010) · Nature · doi:10.1038/nature09002 · Cited by 1,271
The role of nitric oxide in tumour progression
Fukumura, D., Kashiwagi, S., & Jain, R. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1910 · Cited by 1,259
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1×
“PI3K/mTOR pathway activation increases HIF-1α protein levels without altering HIF-1α mRNA levels (Jiang et al., 2001), presumably by increasing HIF-1α translation (Laughner et al., 2001).”
Papapetropoulos, A., García-Cardeña, G., Madri, J. A., & Sessa, W. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119868 · Cited by 1,191
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Fukumura, D., Gohongi, T., Kadambi, A., Izumi, Y., Ang, J., Yun, C.-O., Buerk, D. G., Huang, P. L., & Jain, R. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041359198 · Cited by 1,020
Whitman, M., Downes, C. P., Keeler, M., Keller, T., & Cantley, L. (1988) · Nature · doi:10.1038/332644a0 · Cited by 1,016
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
Regulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., & Maity, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 771
Self-citationRak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Asahara, T., Chen, D., Takahashi, T., Fujikawa, K., Kearney, M., Magner, M., Yancopoulos, G. D., & Isner, J. M. (1998) · Circulation Research · doi:10.1161/01.res.83.3.233 · Cited by 683
Lobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676 · cited 1×
“ANG2 can promote proliferation and migration of endothelial cells, sprouting, and neovascularization in the presence of VEGF (Asahara et al., 1998; Lobov et al., 2002).”
Kim, I., Kim, H. G., So, J.-N., Kim, J. H., Kwak, H. J., & Koh, G. Y. (2000) · Circulation Research · doi:10.1161/01.res.86.1.24 · Cited by 649
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., Placido, S. D., Bianco, A. R., & Tortora, G. (2001) · PubMed · Cited by 643
Xu, Q., Briggs, J., Park, S., Niu, G., Kortylewski, M., Zhang, S., Gritsko, T., Turkson, J., Kay, H., Semenza, G. L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208719 · Cited by 576
(2001) · PubMed · Cited by 557
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 534
Miao, H., Li, D.-Q., Mukherjee, A., Guo, H., Petty, A., Cutter, J., Basilion, J. P., Sedor, J., Wu, J., Danielpour, D., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.009 · Cited by 533
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., Salpekar, A., Pearce, W., Meek, S., Millan, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 520
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
Mazure, N. M., Chen, E. Y., Laderoute, K. R., & Giaccia, A. J. (1997) · Blood · doi:10.1182/blood.v90.9.3322 · Cited by 503
Saharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Winderlich, M., Nottebaum, A., Vestweber, D., Deutsch, U., Koh, G. Y., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1715 · Cited by 471
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.861 · Cited by 469
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype
Naumov, G. N., Bender, E., Zurakowski, D., Kang, S.-Y., Sampson, D., Flynn, E., Watnick, R. S., Straume, O., Akslen, L. A., Folkman, J., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj068 · Cited by 423
Morales-Ruiz, M., Fulton, D., Sowa, G., Languino, L. R., Fujio, Y., Walsh, K., & Sessa, W. C. (2000) · Circulation Research · doi:10.1161/01.res.86.8.892 · Cited by 419
Fukuhara, S., Sako, K., Minami, T., Noda, K., Kim, H. Z., Kodama, T., Shibuya, M., Takakura, N., Koh, G. Y., & Mochizuki, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1714 · Cited by 387
Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium
Yuan, H. T., Khankin, E. V., Karumanchi, S. A., & Parikh, S. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01472-08 · Cited by 373
Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., & Gallick, G. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208513 · Cited by 372
Dimmeler, S., Dernbach, E., & Zeiher, A. M. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01657-4 · Cited by 364
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., & Kerbel, R. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1589 · Cited by 333
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., & Marmé, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25915 · Cited by 329
Daly, C., Wong, V., Burova, E., Wei, Y., Zabski, S., Griffiths, J., Lai, K.-M., Lin, H. C., Ioffe, E., Yancopoulos, G. D., et al. (2004) · Genes & Development · doi:10.1101/gad.1189704 · Cited by 327
Kim, I., Kim, J.-H., Moon, S.-O., Kwak, H. J., Kim, N.-G., & Koh, G. Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203800 · Cited by 306
Maity, A. M., Pore, N., Lee, J. S. H., Solomon, D., & O’Rourke, D. M. (2000) · PubMed · Cited by 302
Self-citationThe PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
Hamada, K., Sasaki, T., Koni, P. A., Natsui, M., Kishimoto, H., Sasaki, J., Yajima, N., Horie, Y., Hasegawa, G., Naito, M., et al. (2005) · Genes & Development · doi:10.1101/gad.1308805 · Cited by 287
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Eph/ephrin molecules—a hub for signaling and endocytosis
Pitulescu, M. E., & Adams, R. H. (2010) · Genes & Development · doi:10.1101/gad.1973910 · Cited by 276
Pore, N., Jiang, Z., Gupta, A., Cerniglia, G., Kao, G. D., & Maity, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3090 · Cited by 268
Self-citationHuang, S. M., Li, J., Armstrong, E. A., & Harari, P. M. (2002) · PubMed · Cited by 263
Kontos, C. D., Stauffer, T. P., Yang, W.-P., York, J. D., Huang, L., Blanar, M. A., Meyer, T., & Peters, K. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4131 · Cited by 226
Falcón, B. L., Hashizume, H., Koumoutsakos, P., Chou, J., Bready, J. V., Coxon, A., Oliner, J. D., & McDonald, D. M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090391 · Cited by 224
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis
Fang, J., Ding, M., Yang, L., Liu, L.-Z., & Jiang, B.-H. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.07.025 · Cited by 205
Angiogenic Actions of Angiopoietin-1 Require Endothelium-Derived Nitric Oxide
Babaei, S., Teichert-Kuliszewska, K., Zhang, Q., Jones, N., Dumont, D. J., & Stewart, D. J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64326-x · Cited by 183
Cellular responses to EGFR inhibitors and their relevance to cancer therapy
Dutta, P. R., & Maity, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.006 · Cited by 181
Self-citationSchnell, C. R., Stauffer, F., Allegrini, P. R., O'Reilly, T., McSheehy, P. M. J., Dartois, C., Stumm, M., Cozens, R., Littlewood-Evans, A., García-Echeverría, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1044 · Cited by 174
PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells
Ma, J., Sawai, H., Ochi, N., Matsuo, Y., Xu, D., Yasuda, A., Takahashi, H., Wakasugi, T., & Takeyama, H. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0154-x · Cited by 158
Pore, N., Liu, S., Haas-Kogan, D. A., O’Rourke, D. M., & Maity, A. M. (2003) · PubMed · Cited by 151
Self-citationThe PI3K p110α isoform regulates endothelial adherens junctions via Pyk2 and Rac1
Cain, R. J., Vanhaesebroeck, B., & Ridley, A. J. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.200907135 · Cited by 143
Cerniglia, G. J., Pore, N., Tsai, J. H., Schultz, S. M., Mick, R., Choe, R., Xing, X., Durduran, T., Yodh, A. G., Evans, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006539 · Cited by 132
Self-citationLarcher, F., Robles, A. I., Durán, H., Murillas, R., Quintanilla, M., Cano, A., Conti, C. J., & Jorcano, J. L. (1996) · PubMed · Cited by 120
Zhang, J., Fukuhara, S., Sako, K., Takenouchi, T., Kitani, H., Kume, T., Koh, G., & Mochizuki, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.192641 · Cited by 114
RACK1 Regulates VEGF/Flt1-mediated Cell Migration via Activation of a PI3K/Akt Pathway
Wang, F., Yamauchi, M., Muramatsu, M., Osawa, T., Tsuchida, R., & Shibuya, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.165605 · Cited by 109
Hypoxia increases Hsp90 binding to eNOS via PI3K-Akt in porcine coronary artery endothelium
Chen, J., & Meyrick, B. O. (2003) · Laboratory Investigation · doi:10.1038/labinvest.3700027 · Cited by 108
Regulation of survivin by PI3K/Akt/p70S6K1 pathway
Zhao, P., Qiao, M., Liu, L.-Z., You, Y.-P., Liu, N., & Jiang, B. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.165 · Cited by 105
Current status of angiogenesis inhibitors combined with radiation therapy
Nieder, C., Wiedenmann, N. E., Andratschke, N. H., & Molls, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.03.006 · Cited by 104
Falcón, B. L., Barr, S. M., Gokhale, P. C., Chou, J., Fogarty, J., Depeille, P., Miglarese, M. R., Epstein, D. M., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3126 · Cited by 103
Serban, D., Leng, J., & Cheresh, D. A. (2008) · Circulation Research · doi:10.1161/circresaha.107.169664 · Cited by 96
HIV Protease Inhibitors Decrease VEGF/HIF-1α Expression and Angiogenesis in Glioblastoma Cells
Pore, N., Gupta, A., Cerniglia, G. J., & Maity, A. M. (2006) · Neoplasia · doi:10.1593/neo.06535 · Cited by 95
Self-citationEssential role of PDK1 in regulating endothelial cell migration
Primo, L., di Blasio, L., Roca, C., Droetto, S., Piva, R., Schaffhausen, B. S., & Bussolino, F. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200607053 · Cited by 94
Tian, T., Nan, K., Wang, S., Liang, X., Lu, C.-X., Guo, H., Wang, W., & Ruan, Z. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq085 · Cited by 84
Zwerts, F., Lupu, F., Vriese, A. D., Pollefeyt, S., Moons, L., Altura, R. A., Jiang, Y., Maxwell, P. H., Hill, P., Oh, H., et al. (2007) · Blood · doi:10.1182/blood-2006-06-028068 · Cited by 83
HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium
Chen, J., Lawrence, M. L., Cunningham, G. R., Christman, B. W., & Meyrick, B. O. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00728.2003 · Cited by 80
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor
Kong, D., Okamura, M., Yoshimi, H., & Yamori, T. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.007 · Cited by 68
Targeting tumors through the HIF system
Ratcliffe, P. J., Pugh, C. W., & Maxwell, P. H. (2000) · Nature Medicine · doi:10.1038/82113 · Cited by 60
Cascio, S., Ferla, R., D'Andrea, A., Gerbino, A., Bazan, V., Surmacz, E., & Russo, A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21843 · Cited by 53
Lelièvre, E., Bourbon, P.-M., Duan, L., Nussbaum, R. L., & Fong, G. (2005) · Blood · doi:10.1182/blood-2004-10-3955 · Cited by 53
Dunaway, C. M., Hwang, Y., Lindsley, C. W., Cook, R. S., Wu, J. Y., Boothby, M. R., Chen, J., & Brantley‐Sieders, D. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00667-10 · Cited by 46
Larcher, F., Franco, M., Bolontrade, M. F., Rodríguez‐Puebla, M. L., Casanova, M., Navarro, M., Yancopoulos, G. D., Jorcano, J. L., & Conti, C. J. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10126 · Cited by 44
Bajaj, A., Zheng, Q., Adam, A. P., Vincent, P. A., & Pumiglia, K. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2648 · Cited by 34
Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils
Martinelli, S., Kostylina, G., Niggli, V., Baumann, C. K., Fey, M. F., Wendel, H.-G., Lowe, S. W., Yousefi, S., & Simon, H.-U. (2006) · Oncogene · doi:10.1038/sj.onc.1209692 · Cited by 19
Hypoxia increases Hsp90 binding to eNOS via PI3K-Akt in porcine coronary artery endothelium
Chen, J., & Meyrick, B. O. (2003) · Laboratory Investigation · doi:10.1038/sj.labinvest.3700027 · Cited by 8
phosphatidylinositol 3-OH Kinase
Choi, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_102876 · Cited by 5
(2001) · PubMed
Cited by
The intersection between aging and cardiovascular disease
North, B. J., & Sinclair, D. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.246876 · Cited by 1,585
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
Sever, R., & Brugge, J. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006098 · Cited by 989
NADPH Oxidases (NOX): An Overview from Discovery, Molecular Mechanisms to Physiology and Pathology
Vermot, A., Petit-Härtlein, I., Smith, S. M. E., & Fieschi, F. (2021) · Antioxidants · doi:10.3390/antiox10060890 · Cited by 766
Metadata
- Authors
- Karar, J., & Maity, A.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2011
- Volume
- 4
- Pages
- 51-51
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2014087704
- Cited by
- 1,461
- References
- 101
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.